These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 25222500)

  • 1. Bone marrow graft as a source of allogeneic hematopoietic stem cells in patients undergoing a reduced intensity conditioning regimen.
    Gomez E; Duléry R; Langlois C; Coiteux V; Terriou L; Magro L; Gauthier J; de Berranger E; Duhamel A; Yakoub-Agha I
    Bone Marrow Transplant; 2014 Dec; 49(12):1492-7. PubMed ID: 25222500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced-intensity conditioning followed by allografting of CD34-selected stem cells and < or =10(6)/kg T cells may have an adverse effect on transplant-related mortality.
    Hartwig UF; Winkelmann N; Wehler T; Kreiter S; Schneider PM; Meyer RG; Ullmann AJ; Huber C; Kolbe K; Herr W
    Ann Hematol; 2005 May; 84(5):331-8. PubMed ID: 15726363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.
    Le Bourgeois A; Mohr C; Guillaume T; Delaunay J; Malard F; Loirat M; Peterlin P; Blin N; Dubruille V; Mahe B; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Lode L; Bene MC; Chevallier P
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):934-9. PubMed ID: 23523970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete donor T cell chimerism predicts lower relapse incidence after standard double umbilical cord blood reduced-intensity conditioning regimen allogeneic transplantation in adults.
    Peterlin P; Delaunay J; Guillaume T; Gastinne T; Mahé B; Dubruille V; Blin N; Le Bourgeois A; Brissot E; Lodé L; Le Gouill S; Moreau P; Mohty M; Chevallier P
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):180-4. PubMed ID: 25175796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.
    Shore T; Harpel J; Schuster MW; Roboz GJ; Leonard JP; Coleman M; Feldman EJ; Silver RT
    Biol Blood Marrow Transplant; 2006 Aug; 12(8):868-75. PubMed ID: 16864057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimerism status after unrelated donor bone marrow transplantation with fludarabine-melphalan conditioning is affected by the melphalan dose and is predictive of relapse.
    Imahashi N; Ohashi H; Terakura S; Miyao K; Sakemura R; Kato T; Sawa M; Yokohata E; Kurahashi S; Ozawa Y; Nishida T; Kiyoi H; Watamoto K; Kohno A; Kasai M; Kato C; Iida H; Naoe T; Miyamura K; Murata M;
    Ann Hematol; 2015 Jul; 94(7):1139-48. PubMed ID: 25680895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.
    Slack JL; Dueck AC; Fauble VD; Sproat LO; Reeder CB; Noel P; Khera N; Betcher JA; Klein JL; Leis JF; Adams RH
    Biol Blood Marrow Transplant; 2013 Aug; 19(8):1167-74. PubMed ID: 23664940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning.
    Mead AJ; Thomson KJ; Morris EC; Mohamedbhai S; Denovan S; Orti G; Fielding AK; Kottaridis PD; Hough R; Chakraverty R; Linch DC; Mackinnon S; Peggs KS
    Blood; 2010 Jun; 115(25):5147-53. PubMed ID: 20371745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen.
    Marsh RA; Rao MB; Gefen A; Bellman D; Mehta PA; Khandelwal P; Chandra S; Jodele S; Myers KC; Grimley M; Dandoy C; El-Bietar J; Kumar AR; Leemhuis T; Zhang K; Bleesing JJ; Jordan MB; Filipovich AH; Davies SM
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1460-70. PubMed ID: 25865646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced-intensity conditioning allogeneic hematopoietic cell transplantation using oral fludarabine as part of the conditioning regimen.
    Delgado J; Marco A; Moreno E; Piñana J; Valcarcel D; Martino R; Briones J; Sureda A; Brunet S; Sierra J
    Cytotherapy; 2009; 11(3):356-61. PubMed ID: 19148841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Higher Total Body Irradiation Dose Intensity in Fludarabine/TBI-Based Reduced-Intensity Conditioning Regimen Is Associated with Inferior Survival in Non-Hodgkin Lymphoma Patients Undergoing Allogeneic Transplantation.
    Hamadani M; Khanal M; Ahn KW; Litovich C; Chow VA; Eghtedar A; Karmali R; Winter A; Fenske TS; Sauter C; Kharfan-Dabaja MA; Awan FT
    Biol Blood Marrow Transplant; 2020 Jun; 26(6):1099-1105. PubMed ID: 32165327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update.
    Bethge WA; Faul C; Bornhäuser M; Stuhler G; Beelen DW; Lang P; Stelljes M; Vogel W; Hägele M; Handgretinger R; Kanz L
    Blood Cells Mol Dis; 2008; 40(1):13-9. PubMed ID: 17869547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant.
    Devine SM; Sanborn R; Jessop E; Stock W; Huml M; Peace D; Wickrema A; Yassine M; Amin K; Thomason D; Chen YH; Devine H; Maningo M; van Besien K
    Bone Marrow Transplant; 2001 Sep; 28(6):557-62. PubMed ID: 11607768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen.
    Mohty M; Bay JO; Faucher C; Choufi B; Bilger K; Tournilhac O; Vey N; Stoppa AM; Coso D; Chabannon C; Viens P; Maraninchi D; Blaise D
    Blood; 2003 Jul; 102(2):470-6. PubMed ID: 12649133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic hematopoietic cell transplantation using fludarabine plus myeloablative busulfan and melphalan confers promising survival in high-risk hematopoietic neoplasms: a single-center retrospective analysis.
    Edahiro T; Kawase T; Nagoshi H; Fujino K; Toishigawa K; Miyama T; Mino T; Yoshida T; Morioka T; Hirata Y; Noma M; Fujii T; Nishizawa M; Fukushima N; Ichinohe T
    Hematology; 2021 Dec; 26(1):186-198. PubMed ID: 33594942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis.
    Pérez-Simón JA; Martino R; Caballero D; Valcarcel D; Rebollo N; de la Cámara R; de Oteiza JP; Heras I; Calvo MV; Sierra J; San Miguel JF;
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):664-71. PubMed ID: 18489992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stable engraftment after a conditioning regimen with fludarabine and melphalan for bone marrow transplantation from an unrelated donor.
    Inamoto Y; Oba T; Miyamura K; Terakura S; Tsujimura A; Kuwatsuka Y; Tokunaga M; Kasai M; Murata M; Naoe T; Kodera Y
    Int J Hematol; 2006 May; 83(4):356-62. PubMed ID: 16757439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term results of allogeneic hematopoietic stem cell transplantation after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
    Krejci M; Brychtova Y; Doubek M; Tomiska M; Navratil M; Racil Z; Dvorakova D; Horky O; Lengerova M; Pospisilova S; Mayer J
    Neoplasma; 2011; 58(5):406-14. PubMed ID: 21744994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
    Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
    Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation.
    Kottaridis PD; Milligan DW; Chopra R; Chakraverty RK; Chakrabarti S; Robinson S; Peggs K; Verfuerth S; Pettengell R; Marsh JC; Schey S; Mahendra P; Morgan GJ; Hale G; Waldmann H; Ruiz de Elvira MC; Williams CD; Devereux S; Linch DC; Goldstone AH; MacKinnon S
    Cytotherapy; 2001; 3(3):197-201. PubMed ID: 12171726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.